🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Johnson & Johnson, Blink, Farfetch Rise Premarket; Tesla Falls

Published 11/12/2021, 07:59 AM
Updated 11/12/2021, 08:00 AM
© Reuters.
GS
-
BIIB
-
NVDA
-
JNJ
-
ALXN
-
TSLA
-
YNAP
-
AZN
-
BLNK
-
JD
-
BABA
-
CFRUY
-
HPE
-
FTCHQ
-
NRDE
-

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Friday, November 12th. Please refresh for updates.

  • Johnson & Johnson (NYSE:JNJ) stock rose 2.8% after the company said it will break into two separate companies, splitting off its consumer health division from its large pharmaceuticals unit. 

  • Blink Charging (NASDAQ:BLNK) stock rose 5.7% after the provider of charging stations reported its third-quarter revenue jumped more than seven-fold, well ahead of expectations.

  • Alibaba (NYSE:BABA) ADRs fell 1.2% after China’s largest ecommerce platform reported that its sales grew 8.5% during the Singles Day shopping festival, the first time in history that its growth has slowed below 10%. Smaller rival JD.com (NASDAQ:JD) stock fell 0.4% in sympathy even though it reported that its sales rose around 29% from the previous year. 

  • Tesla (NASDAQ:TSLA) stock fell 0.5% after regulatory filings showed Friday that Chief Executive Officer Elon Musk sold more shares of the electric car maker, days after he sold $5 billion of the stock, or 3% of his total holdings, the first such move since 2016.

  • Farfetch (NYSE:FTCH) stock rose 3.6% after Swiss luxury goods firm Richemont (OTC:CFRUY) revealed it was in advanced talks to expand its partnership with the online luxury fashion retail platform, including through the sale of a stake in its underperforming e-commerce unit Yoox Net-a-Porter (MI:YNAP).

  • AstraZeneca (NASDAQ:AZN) ADRs fell 4.2% as the Anglo-Swedish drugmaker reported third-quarter profit short of estimates, citing high integration costs for newly-acquired Alexion (NASDAQ:ALXN) and disappointing sales of its cancer drug Tagrisso in China.

  • Biogen (NASDAQ:BIIB) stock rose 2.6% after late stage studies reported positive results for the biotech company’s Alzheimer's drug Aduhelm.

  • Nvidia (NASDAQ:NVDA) stock fell 1.5% after Wedbush downgraded its investment stance on the tech company to ‘neutral’ from ‘outperform’, citing its elevated valuation having gained over 45% this month.

  • Hewlett Packard Enterprise (NYSE:HPE) stock fell 4.6% after Goldman Sachs (NYSE:GS) downgraded its stance on the company to ‘sell’ from ‘neutral’, citing the risk of corporate spending on information technology slowing. 

  • Lordstown Motors (NASDAQ:RIDE) stock fell 9.6% after the auto startup delayed the commercial production and deliveries of its first product, an all-electric pickup called the Endurance, once more.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.